Telefonla Randevu için:
Laboratuvar Sistemi

2026 Yayınlarımız: "Locally Advanced Disease and Clinical Outcomes of Pheochromocytomas and Paragangliomas: Insights from a Multicenter Study."

2026 Yayınlarımız: "Locally Advanced Disease and Clinical Outcomes of Pheochromocytomas and Paragangliomas: Insights from a Multicenter Study."

Küçült Yazı Tipi Büyüt
Locally Advanced Disease and Clinical Outcomes of Pheochromocytomas and Paragangliomas: Insights from a Multicenter Study.
Icin BB, Uzun O, Cakir B, Tural Balsak BO, İmga NN, Soltanova L, Kadioglu P, Kimyon OS, Ciftci S, Alibakan OK, Niyazioglu M, Sarıdas FM, Gul OO, Erol RS, Haydardedeoglu FE, Pekkolay Z, Arda Ozkan EM, Tuna MM, Yivli E, Bayraktaroglu T, Yaylali GF, Evren B, Cınar N, Akbaba G, Catak M, Ekici B, Celik M, Ozbay UN, Tuzun D, Uc ZA, Kilinc F, Elbuken G, Zuhur SS.Endocr Pract. 2026 Oct 15:S1530-891X(26)01287-5. doi: 10.1016/j.eprac.2026.10.005. Online ahead of print.PMID: 42880592
https://doi.org/10.1016/j.eprac.2026.10.005Get rights and content

Highlights

  • •
    Locally advanced disease (LAD) in patients with pheochromocytomas and paragangliomas (PPGLs) has been suggested to be associated with worse clinical outcomes.
  • •
    LAD was identified in 28.5% of 389 patients and persistent/recurrent disease occurred in 17.1% with LAD versus 6.1% without LAD.
  • •
    The prognostic association of LAD persisted after excluding patients with distant metastatic disease at diagnosis.
  • •
    In stage I–II disease, LAD was associated with shorter disease-free survival and provided additional prognostic information beyond TNM stage.
  • •
    Local invasion and proliferative activity may provide complementary prognostic information.


Yayınlanma Tarihi : 29.10.2026
Fotoğraf Başlığı